Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Cancer: early-phase trial registry
89 of 260 indexed Head and Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #39 of 28,707 conditions by registered trial count.
260 US clinical trials · 89 currently recruiting · #39 of 28,707 conditions by registered trial count
Head and Neck Cancer: 260 US clinical trials tracked, 89 recruiting.
Head and Neck Cancer is the subject of 260 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 137 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition head-and-neck-cancer
OPEN 89 | RECR 34% | LATE 13 | EARLY 137 | RANK #39 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Recurrent Malignant Solid Neoplasm (34% recruiting · 38 trials)
Head and Neck Cancer lists 89 open slots (34% of 260 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Cancer is recruiting below its size-band peers.
89 of 260 indexed trials (34.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 19 of 260 trials (7.3%). 124 distinct sponsors appear on at least one study for this condition label.
-
Most Head and Neck Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 251 trials that report a genuine target (sentinel values excluded). 165 of those (65.7%) plan for fewer than 100 participants.
-
Head and Neck Cancer research is mostly interventional.
213 interventional and 47 observational studies make up this index (81.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
260 total, page 3 of 6
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT04180371
Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors
Memorial Sloan Kettering Cancer Center
NCT00581906
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
NCT01220583
Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers
M.D. Anderson Cancer Center
NCT03114501
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
ALX Oncology
NCT04675294
Depression and Adherence in Head and Neck Cancer
M.D. Anderson Cancer Center
NCT00498875
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Incyte Biosciences International Sàrl
NCT05287113
Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
M.D. Anderson Cancer Center
NCT02662907
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology
NCT04675333
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
BeiGene
NCT05909904
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium
NCT05060432
Alcohol Cessation Among Head and Neck Cancer Survivors
Northwell Health
NCT05570851
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Rakuten Medical
NCT03769506
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT02923570
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
University of Chicago
NCT02841748
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer
M.D. Anderson Cancer Center
NCT03491176
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Trisha Wise-Draper
NCT02641093
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
Susanne Arnold
NCT02994069
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT02270814
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study
Duke University
NCT03506451
Tumescence in HNC Skin Graft Reconstruction
University of California, Davis
NCT04967391
A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT05207098
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT04609280
Smoking Cessation Treatment for Head & Neck Cancer Patients
M.D. Anderson Cancer Center
NCT01098955
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT00076310
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06110195
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
NCT06187103
A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
Varian, a Siemens Healthineers Company
NCT05975619
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05704985
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Trisha Wise-Draper
NCT03355560
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT03336606
Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus
University of California, San Francisco
NCT05671861
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
NCT05226871
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
NCT02919683
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
University of Oklahoma
NCT04373642
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Providence Health & Services
NCT04938609
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06137274
Safety and Efficacy of APG-157 in Head and Neck Cancer
Aveta Biomics
NCT05312710
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
University of Wisconsin, Madison
NCT05820711
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Trisha Wise-Draper
NCT04313504
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Providence Health & Services
NCT03247712
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
Dana-Farber Cancer Institute
NCT03085719
Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
M.D. Anderson Cancer Center
NCT05327270
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
University of Wisconsin, Madison
NCT05816785
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
American College of Radiology
NCT05540899
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 63 |
| Phase 2 | 74 |
| Phase 3 | 11 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Cancer page
260 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Head and Neck Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Head and Neck Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Cancer condition card totals 260 registered trials; most-linked intervention cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.